New Statin-CBD combo drug enters first human safety trial
NCT ID NCT06615284
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety of Atorvo+™, a new drug that combines the common cholesterol-lowering medication atorvastatin with cannabidiol (CBD). The trial involved 24 healthy adults aged 40-75 to see how the body processes the drug and if it causes any side effects. The goal is to find a better way to manage cholesterol and lower the risk of heart disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atorvo+™ (a combination of atorvastatin and cannabidiol (CBD))
What this could lead to
If successful, this could lead to a new treatment option for managing cholesterol and reducing heart disease risk.
What could go wrong
This is an early Phase 1 safety study in only 24 healthy adults, so it does not yet test effectiveness. Side effects like muscle pain or liver issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network
Melbourne, Australia